Biotech founders
Preparing for fundraising, platform positioning, or strategic inflection points where the evidence plan needs to match the biology.
Integrated biology, translated into strategy.
Scientific-strategy consulting for biotech, spinout, and investor teams in metabolic disease — where biology crosses organs, labels, and markets faster than the evidence.
15yrsIn metabolic-disease research, across three labs
20yrsIn transactional law and dealmaking
Published research
Evidence-graded — and on the record
Openly licensed and built to be citable, with registered DOIs on our deposited reports and essays. See how we publish and cite →
Insight · Founder essay
GLP-1’s Forgotten Patients
GLP-1s won the average patient; the opening is everyone they leave behind — the lean and progressing, the older and frail, and the patient who stops.
Read the essay →
Founder Report
When Biology Crosses Categories Before Medicine Does
Why biology routinely outruns the labels, specialties, and evidence systems built to contain it — and what that means for development strategy.
→ Strategy ReportMetabolism as Platform Medicine
What cross-organ metabolic biology means for development strategy, endpoints, labels, reimbursement, and evidence architecture.
→ Founder EssayThe Translational Gap in Metabolic Disease
The clinical problem behind the metabolic-integration series — where discovery science and patient outcomes still fail to meet.
→
Target Audiences
Who we help
Academic spinouts
Turning discoveries into investable narratives, credible development plans, and clear scientific stories.
Investors & BD teams
Needing independent diligence that tests the evidence architecture behind the mechanism, the data, and the broader strategic claim.
Medtech-adjacent teams
Working where metabolic disease, clinical workflow, digital health, and physician adoption intersect.
What we do
We turn mechanism into decision-ready strategy.
Two complementary, partner-led lanes: we turn complex biology into testable hypotheses and defensible strategy — and we structure the partnerships, licensing, and financing that follow.
Strategic Scientific Hypothesis Engagement
A focused advisory deliverable for teams facing a scientific-strategic decision. We start from the data already in hand, identify the mechanistic gaps that matter most, and prioritize the experiments or readouts that would most strengthen the scientific story, investor narrative, and development strategy.
Deal & Partnering Strategy
Partner-led, for teams negotiating a partnership, license, or financing. We help structure the deal, negotiate the terms, and protect founder equity — so the value created in the science is not given away at the table.
Signature Expertise
Metabolic disease is our center of gravity.
It is where integration matters most: connected biology moving across major metabolic organs while evidence is still built one indication at a time.
Our read is grounded in islet and incretin biology — the mechanisms behind today’s metabolic therapies, and behind what those drugs do not yet address: durability, body composition, and overlooked patients.
Explore metabolic strategy →
Mechanism-aware
We read the biology, not just the headline.
Evidence-graded
We distinguish approved indications, trial findings, company-reported signals, and emerging hypotheses.
Decision-oriented
Every analysis is built around a strategic decision — not a literature dump.
Integral BioStrategy is partner-led by Ivan A. Valdez, PhD and Alfred Atallah, JD — combining deep science with transaction-informed judgment, with specialized advisors added by scope. Meet the partners →
Have a scientific strategy question?
For confidential biotech, spinout, investor, or strategic diligence inquiries, start with a brief scoping conversation.
Request a confidential scoping callPrefer email? [email protected]